标题
Therapeutic landscape in mutational triple negative breast cancer
作者
关键词
Somatic, Germline, Mutation, Therapeutic, TNBC
出版物
Molecular Cancer
Volume 17, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-07-14
DOI
10.1186/s12943-018-0850-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
- (2018) Charissa Kim et al. CELL
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field
- (2017) Clinton Yam et al. ONCOLOGIST
- PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
- (2017) Nandini Dey et al. PHARMACOLOGY & THERAPEUTICS
- Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency
- (2017) Masahito Kawazu et al. PLoS Genetics
- Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer
- (2017) Guido Neidhardt et al. JAMA Oncology
- Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer
- (2017) Reva K. Basho et al. JAMA Oncology
- Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer
- (2017) Eric Hahnen et al. JAMA Oncology
- Somatic gene mutation analysis of triple negative breast cancers
- (2016) J.L. Dillon et al. BREAST
- Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial
- (2016) Milagros González-Rivera et al. BREAST CANCER RESEARCH AND TREATMENT
- Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer
- (2016) Juan Zhang et al. BREAST CANCER RESEARCH AND TREATMENT
- Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)
- (2016) WM Sikov et al. CANCER RESEARCH
- Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)
- (2016) G von Minckwitz et al. CANCER RESEARCH
- RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation
- (2016) Robert A. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
- (2016) David Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology
- (2016) Paul S Weisman et al. MODERN PATHOLOGY
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- (2016) Hope S. Rugo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the RB-E2F pathway in breast cancer
- (2016) J Johnson et al. ONCOGENE
- The topography of mutational processes in breast cancer genomes
- (2016) Sandro Morganella et al. Nature Communications
- The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer
- (2015) C. Villarreal-Garza et al. BREAST CANCER RESEARCH AND TREATMENT
- Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer
- (2015) Michelle W. Wong-Brown et al. BREAST CANCER RESEARCH AND TREATMENT
- Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)
- (2015) Andrew Tutt et al. CANCER RESEARCH
- Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
- (2015) Fergus J. Couch et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis
- (2015) Cezary Cybulski et al. LANCET ONCOLOGY
- Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
- (2015) Sara A Hurvitz et al. LANCET ONCOLOGY
- Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer
- (2015) Kokoro Kobayashi et al. SURGERY TODAY
- Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness
- (2015) Pradip De et al. NEOPLASIA
- Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†
- (2014) A. M. Gonzalez-Angulo et al. ANNALS OF ONCOLOGY
- Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing
- (2014) Priyanka Sharma et al. BREAST CANCER RESEARCH AND TREATMENT
- Frequency of mutations in individuals with breast cancer referred forBRCA1andBRCA2testing using next-generation sequencing with a 25-gene panel
- (2014) Nadine Tung et al. CANCER
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer
- (2014) Johanna I. Kiiski et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort
- (2013) Rachel Greenup et al. ANNALS OF SURGICAL ONCOLOGY
- Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women
- (2013) E. Tilch et al. BREAST CANCER RESEARCH AND TREATMENT
- Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer
- (2013) J. M. Balko et al. CANCER RESEARCH
- The Omics of Triple-Negative Breast Cancers
- (2013) H. Xu et al. CLINICAL CHEMISTRY
- Low prevalence of germlinePALB2mutations in Australian triple-negative breast cancer
- (2013) Michelle W. Wong-Brown et al. INTERNATIONAL JOURNAL OF CANCER
- Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53
- (2013) M. A. Gadhikar et al. MOLECULAR CANCER THERAPEUTICS
- The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
- (2013) Matthew J. Ellis et al. Cancer Discovery
- Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
- (2012) Libero Santarpia et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
- (2012) Martin Schuler et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
- (2012) Cynthia X. Ma et al. BREAST CANCER RESEARCH AND TREATMENT
- Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer
- (2012) Ning Lv et al. Cancer Epidemiology
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
- (2012) Cynthia X. Ma et al. JOURNAL OF CLINICAL INVESTIGATION
- The landscape of cancer genes and mutational processes in breast cancer
- (2012) Philip J. Stephens et al. NATURE
- The clonal and mutational evolution spectrum of primary triple-negative breast cancers
- (2012) Sohrab P. Shah et al. NATURE
- Sequence analysis of mutations and translocations across breast cancer subtypes
- (2012) Shantanu Banerji et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women
- (2011) E. Comen et al. BREAST CANCER RESEARCH AND TREATMENT
- Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer
- (2011) Anne-Renee Hartman et al. CANCER
- Triple-negative breast cancer in Hispanic patients
- (2011) Fernando Lara-Medina et al. CANCER
- Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73
- (2010) Su Wei Wong et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
- (2010) Paula M. Fracasso et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Nuclear phosphoinositide 3-kinase controls double-strand break DNA repair
- (2010) A. Kumar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients
- (2009) Yanping Lin et al. BMC CANCER
- The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
- (2009) SR Young et al. BMC CANCER
- Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
- (2009) O. K. Mirzoeva et al. CANCER RESEARCH
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
- The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype
- (2009) T. Heikkinen et al. CLINICAL CANCER RESEARCH
- Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
- (2009) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Distribution of Molecular Breast Cancer Subtypes in Middle Eastern-Saudi Arabian Women: A Pilot Study
- (2009) Dalal M. Al-Tamimi et al. ULTRASTRUCTURAL PATHOLOGY
- Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers
- (2008) Tatsuya Toyama et al. BMC CANCER
- Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer
- (2008) Deann P. Atchley et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now